What Companies Does Vivek Ramaswamy Own? A Quick Look at His Business Ventures

seriosity featured image

Vivek Ramaswamy is a name that has been making waves in the business and political world alike. He is a successful entrepreneur, investor, and philanthropist who has achieved great heights in his career. One of the questions that people often ask about him is what companies he owns and operates.

Vivek Ramaswamy owns multiple companies. A desk with company logos, a globe, and a stack of business documents

Ramaswamy is the founder and CEO of Roivant Sciences, a biopharmaceutical company that is focused on developing innovative therapies for patients. The company has made significant strides in the field of drug development and has been successful in bringing several drugs to market. He has also founded and invested in other biotech companies, including Myovant Sciences and Urovant Sciences.

Key Takeaways

  • Vivek Ramaswamy is the founder and CEO of Roivant Sciences, a biopharmaceutical company that is focused on developing innovative therapies for patients.
  • Ramaswamy has founded and invested in other biotech companies, including Myovant Sciences and Urovant Sciences.
  • In addition to his business ventures, Ramaswamy has also entered the world of politics, running for the Republican Party nomination in the 2024 United States presidential election.

Vivek Ramaswamy’s Early Life and Education

Vivek Ramaswamy's early life and education, showcasing his business ventures and companies owned

Vivek Ramaswamy was born on August 9, 1985, in Cincinnati, Ohio. He grew up in a family of Indian immigrants and attended St. Xavier High School, where he was a valedictorian of his class. Ramaswamy then went to Harvard University, where he studied molecular and cellular biology, and played on the varsity tennis team. He graduated magna cum laude in 2007.

Academic Background at Harvard and Yale

After graduating from Harvard, Ramaswamy worked for QVT Financial, a hedge fund based in New York City. He then pursued a law degree at Yale University, where he was an editor of the Yale Law Journal. In 2013, he graduated from Yale Law School.

Early Career and Transition into Biotech

Ramaswamy’s career in biotech began in 2014 when he founded Roivant Sciences, a pharmaceutical company that specializes in developing drugs for rare diseases. The company has raised over $3 billion in funding and has over 800 employees. Ramaswamy has also founded several other companies, including Axovant Sciences, a biotech company that focuses on developing treatments for Alzheimer’s disease.

Ramaswamy is known for his entrepreneurial spirit and his ability to identify and capitalize on emerging trends in the biotech industry. He has been recognized for his contributions to the field of biotech and was named to Forbes’ 30 Under 30 list in 2015.

Throughout his career, Ramaswamy has remained committed to his academic roots. He has served on the board of trustees at Harvard University and has been a guest lecturer at Yale Law School. He is also a member of the board of directors at the Duke University School of Medicine.

In summary, Vivek Ramaswamy is a successful entrepreneur and biotech expert who has made significant contributions to the field of rare disease drug development. His academic background in molecular and cellular biology, law, and business has prepared him well for his current role as the CEO of Roivant Sciences.

Roivant Sciences and Biotech Ventures

A bustling office with the logos of Roivant Sciences and Biotech Ventures prominently displayed, indicating ownership by Vivek Ramaswamy

Founding of Roivant and Subsidiaries

Vivek Ramaswamy, a former hedge fund manager, founded Roivant Sciences in 2014 with the goal of developing innovative medicines to improve patient outcomes. Roivant Sciences is a biopharmaceutical company that focuses on the development and commercialization of transformative therapies. The company’s subsidiaries include Axovant, Enzyvant, Dermavant, and Urovant, among others.

Axovant is a pharmaceutical company that focuses on developing treatments for neurological diseases. Enzyvant is a biopharmaceutical company that focuses on developing treatments for rare diseases. Dermavant is a dermatology-focused biopharmaceutical company, while Urovant focuses on developing treatments for urologic conditions.

Pharmaceutical Developments and Clinical Trials

Roivant Sciences has been involved in several pharmaceutical developments and clinical trials. In 2018, the company announced positive results from a Phase 3 clinical trial of its investigational drug RVT-101 for the treatment of dementia with Lewy bodies. The company is also developing RVT-104, a drug for the treatment of Alzheimer’s disease.

In 2020, Roivant Sciences announced that it had entered into a partnership with Sumitomo Dainippon Pharma to develop and commercialize three clinical-stage assets, including RVT-1201, a treatment for schizophrenia. The company is also collaborating with GlaxoSmithKline on the development of a therapy for chronic obstructive pulmonary disease.

Partnerships and Expansion

Roivant Sciences has expanded its reach through partnerships and acquisitions. In 2019, the company acquired Silicon Therapeutics, a privately held biotechnology company focused on developing treatments for diseases with high unmet medical needs. The acquisition strengthened Roivant’s computational drug discovery capabilities.

In 2020, Roivant Sciences announced the launch of a new subsidiary, Metavant, which focuses on the development of treatments for metabolic diseases. The company also announced the launch of another subsidiary, Immunovant, which focuses on developing treatments for autoimmune diseases.

Overall, Roivant Sciences and its subsidiaries have made significant strides in the biopharmaceutical industry under the leadership of Vivek Ramaswamy.

Financial Success and Public Offerings

A bustling stock exchange floor with companies' logos displayed on screens, investors celebrating, and a banner reading "Public Offerings" in the background

Vivek Ramaswamy is a well-known entrepreneur and investor who has made a name for himself in the world of finance. He has been recognized by Forbes for his financial success, and has made headlines for his involvement in several high-profile public offerings.

Net Worth and Forbes Recognition

According to Forbes, Vivek Ramaswamy has a net worth of $2.8 billion. He has made his fortune through various ventures, including his investment firm Strive Asset Management and his biotechnology company Roivant Sciences.

Forbes has recognized Ramaswamy’s financial success by including him on their list of the world’s billionaires. In 2022, he was ranked #1,175 on the list, and was noted for his involvement in several successful public offerings.

Roivant’s Initial Public Offering

One of Ramaswamy’s most notable public offerings was the initial public offering (IPO) of his biotechnology company Roivant Sciences. In 2016, Roivant Sciences went public on the NASDAQ stock exchange, raising $1.1 billion in capital.

The IPO was a major success, and helped to establish Roivant Sciences as a major player in the biotechnology industry. Ramaswamy’s leadership and vision were key factors in the success of the offering, and he has continued to build on that success in the years since.

Overall, Vivek Ramaswamy’s financial success and involvement in high-profile public offerings have made him a prominent figure in the world of finance. His net worth and recognition by Forbes are a testament to his skill as an entrepreneur and investor.

Entry into Politics and Public Service

Vivek Ramaswamy owns several companies in the healthcare and biotech industries, as well as in the field of public policy and politics

Presidential Ambitions and Campaign

Vivek Ramaswamy, the founder of Roivant Sciences, announced his intention to run for the Republican nomination for President of the United States on February 21, 2023. According to Politico, he sold four million shares in Roivant at $7.95 each on the day after his announcement. Ramaswamy’s campaign focused on appealing to conservatives and fundraising from voters who shared his views on issues such as social justice, immigration, and national security.

Political Views and Republican Party Involvement

Ramaswamy has been a vocal critic of what he calls “woke culture” and has written a book on the topic, titled “Woke, Inc.” He has also been involved in Republican Party politics for several years, serving as a delegate to the 2016 Republican National Convention and donating to the campaigns of Republican candidates such as Donald Trump and Nikki Haley. According to Forbes, Ramaswamy stepped down as CEO of Roivant in 2021 to focus on his political ambitions.

Ramaswamy’s personal financial disclosure and income tax returns became a topic of discussion during his presidential campaign. According to The New York Times, Ramaswamy’s financial disclosure showed that he had earned over $600 million from 2014 to 2022. However, he also reported losses of over $100 million in 2020, which he attributed to the COVID-19 pandemic.

Strive Asset Management and Investment Philosophy

Strive Asset Management's logo displayed on a modern office building facade

Strive Asset Management is an investment firm founded in 2022 by Vivek Ramaswamy, a former hedge fund manager and biotech entrepreneur. The firm has gained attention for its anti-ESG (environmental, social, and governance) stance, which Ramaswamy has criticized for being “woke capitalism” that prioritizes social justice over profits.

Critique of ESG and Social Justice Investing

Ramaswamy has argued that ESG investing is not only misguided but also harmful to the economy and society. He believes that companies should focus on maximizing shareholder value and that social justice issues should be addressed by governments, not businesses. He has also criticized the lack of transparency and standardization in ESG metrics, which he claims allows companies to manipulate their scores to meet investors’ demands.

Partnership with Peter Thiel and Other Investors

Strive has attracted a number of high-profile investors, including Peter Thiel, Viking Global Investors, Bill Ackman, and Narya Capital. The firm’s investment philosophy is centered around a long-term, value-oriented approach that seeks to identify undervalued companies with strong fundamentals. Strive’s portfolio consists of a mix of individual stocks and index funds, with a focus on sectors such as healthcare, technology, and energy.

According to a Wall Street Journal report, Strive has reached $1 billion in assets under management, thanks in part to Ramaswamy’s high-profile political campaign. However, the firm has also faced legal challenges over its anti-ESG stance, with some investors accusing Strive of putting their money at risk by ignoring social and environmental risks.

Overall, Strive Asset Management’s investment philosophy is rooted in a contrarian approach to ESG and social justice investing. While the firm’s stance has drawn criticism from some quarters, its success in attracting high-profile investors and achieving strong returns suggests that there is demand for a more traditional, profit-focused approach to investing.

Cultural and Social Commentary

A bustling city street with billboards and storefronts, showcasing various companies owned by Vivek Ramaswamy, each reflecting cultural and social commentary

“Woke, Inc.” and Criticism of Corporate America

Vivek Ramaswamy has been a vocal critic of what he calls “Woke, Inc.,” which he defines as the “intersection of big business and left-wing ideology.” In his book, “Woke, Inc.: Inside Corporate America’s Social Justice Scam,” Ramaswamy argues that many corporations are more interested in virtue signaling and appeasing the left than in actually making a positive impact on society. He believes that corporate America’s obsession with “wokeness” has led to a culture of censorship and intolerance, where anyone who disagrees with the prevailing orthodoxy is branded a bigot or a heretic.

Ramaswamy’s views on “Woke, Inc.” have made him a controversial figure, with some accusing him of being a conservative ideologue. However, Ramaswamy insists that he is not a partisan and that his criticism of corporate America is motivated by a desire to see businesses do more to help society.

Public Stance on Social and Environmental Issues

Despite his criticism of “Woke, Inc.,” Ramaswamy has taken public stances on various social and environmental issues. For example, he has been a vocal advocate for gender equality and has criticized the gender pay gap. He has also spoken out against climate change, although he has been critical of what he calls “climate-ism,” which he defines as the “dogmatic belief that climate change is an existential threat to humanity.”

Ramaswamy is a registered Democrat and has donated to various Democratic candidates and causes. However, he has also been critical of the Democratic Party, particularly on issues related to free speech and censorship. He has argued that the left’s obsession with political correctness and cancel culture is damaging to society and that it is important to protect free speech, even if it means tolerating views that one disagrees with.

In terms of his investments, Ramaswamy has holdings in various companies, including Microsoft, Home Depot, and Lockheed Martin, among others. While some of these companies may be seen as at odds with his public stances on social and environmental issues, Ramaswamy has defended his investments, arguing that he is simply trying to make money and that his personal beliefs do not necessarily have to align with his investments.

Personal Life and Family Background

A cozy living room with family photos on the walls, a bookshelf filled with personal mementos, and a dining table set for a family meal

Indian Heritage and Family Influence

Vivek Ramaswamy is an Indian-American entrepreneur and author who was born on August 9, 1985, in Cincinnati, Ohio. He grew up in a family with a strong Indian heritage, and his parents were both immigrants from the southern Indian state of Kerala. Ramaswamy’s family background has had a significant impact on his life and career.

Growing up, Ramaswamy was exposed to Indian culture and traditions, which have influenced his personal and professional choices. He has spoken about the importance of his Indian heritage in shaping his values and beliefs. Ramaswamy’s parents instilled in him a strong work ethic and a commitment to education, which have been crucial to his success as an entrepreneur.

Lifestyle and Personal Interests

Ramaswamy is a private person and does not share much about his personal life. However, he has spoken about his lifestyle and personal interests in interviews and articles.

Ramaswamy is a fitness enthusiast and enjoys working out regularly. He has also spoken about his love for reading and writing. In his free time, he enjoys reading books on a wide range of topics, including history, philosophy, and science. Ramaswamy has also authored a book called “Woke, Inc.,” which criticizes corporate America’s growing focus on social justice issues.

As an Indian-American, Ramaswamy has a strong connection to his Indian heritage. He has spoken about his love for Indian food and has even shared recipes for some of his favorite dishes. Ramaswamy is also a fan of Indian classical music and has attended concerts by Indian musicians.

Overall, Ramaswamy’s personal life and family background have played a significant role in shaping his values, beliefs, and interests. His Indian heritage and family influence have been crucial to his success as an entrepreneur, and his commitment to fitness, reading, and writing reflect his dedication to personal growth and self-improvement.

Controversies and Challenges

Vivek Ramaswamy's companies face controversies and challenges. Show a group of diverse business logos with conflicting symbols

Legal and Financial Scrutinies

Vivek Ramaswamy, the founder of Roivant Sciences, has faced legal and financial challenges in the past. In 2023, two former employees of Strive Asset Management, a company Ramaswamy co-founded, sued him for pressuring them to violate securities laws. The lawsuits alleged that Strive Asset Management forced employees to purchase shares in a private fund, even though they had no investment experience. The former employees claimed that they were misled into believing that the fund was a safe investment, and that they lost money as a result.

Furthermore, in 2024, a Newsweek article accused Ramaswamy of being a fraud. The article claimed that Ramaswamy criticized ESG (Environmental, Social, and Governance) principles, while Roivant Sciences’ major institutional investors, including Morgan Stanley, Viking Global, and BlackRock, were among its supporters. The article also alleged that Ramaswamy’s statements about his companies’ financial performance were misleading.

Setbacks in Biotech and Pharmaceutical Fields

Ramaswamy’s companies have faced setbacks in the biotech and pharmaceutical fields. In 2024, Roivant Sciences distanced itself from Ramaswamy’s allegations of FDA corruption. Ramaswamy, who was running for the Republican presidential nomination, accused the FDA of being corrupt and inefficient. Roivant Sciences, however, issued a statement saying that Ramaswamy’s views did not reflect those of the company.

Another setback occurred in 2022, when Roivant Sciences’ subsidiary, Myovant Sciences, faced a delay in the FDA approval process for its drug, Relugolix. The drug was intended to treat uterine fibroids and endometriosis. The delay caused Roivant Sciences’ stock price to drop by 30%. Despite these setbacks, Ramaswamy has continued to invest in biotech and pharmaceutical companies.